Aytu BioPharma, Inc.AYTUNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+111.6%
5Y CAGR+61.4%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+111.6%/yr
vs +66.5%/yr prior
5Y CAGR
+61.4%/yr
Recent acceleration
Acceleration
+45.1pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
11x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 694.66% |
| Q3 2025 | -122.05% |
| Q2 2025 | 143.42% |
| Q1 2025 | -322.20% |
| Q4 2024 | 344.12% |
| Q3 2024 | -51.02% |
| Q2 2024 | -210.24% |
| Q1 2024 | -88.15% |
| Q4 2023 | 36.02% |
| Q3 2023 | -102.25% |
| Q2 2023 | 422.26% |
| Q1 2023 | -19.10% |
| Q4 2022 | 73.33% |
| Q3 2022 | -28.94% |
| Q2 2022 | 22.16% |
| Q1 2022 | -3.32% |
| Q4 2021 | -132.71% |
| Q3 2021 | 39.69% |
| Q2 2021 | 28.38% |
| Q1 2021 | -200.19% |
| Q4 2020 | 63.37% |
| Q3 2020 | -2.81% |
| Q2 2020 | 32.61% |
| Q1 2020 | -88.91% |
| Q4 2019 | -104.14% |
| Q3 2019 | 13.99% |
| Q2 2019 | -4.94% |
| Q1 2019 | 23.06% |
| Q4 2018 | -56.78% |
| Q3 2018 | 39.59% |
| Q2 2018 | -11.41% |
| Q1 2018 | -31.51% |
| Q4 2017 | 26.48% |
| Q3 2017 | -29.03% |
| Q2 2017 | -36.65% |
| Q1 2017 | 15.65% |
| Q4 2016 | 46.81% |
| Q3 2016 | -100.10% |
| Q2 2016 | -11.71% |
| Q1 2016 | 30.85% |